In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xalkori And The Art Of Modern Drug Development

Executive Summary

Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.


Related Content

Deals Of The Week: Value Surprise!
Epizyme Execs On Company’s IPO, Clinical Progress And Diagnostic Strategy
Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile
Pfizer Turns To Ventana To Expand Companion Dx Options For Xalkori
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
Back To School: Big Pharmas Test New Models For Tapping Academia
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
Pfizer's Increasingly Specialist Focus
Pfizer Restructures for a More Flexible Future
With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts